



## Neuro-Oncology Symposium 2023: Immunotherapy in Neuro-oncology

### 5/20/2023

This activity was created to address the professional practice gaps listed below:

- Promoting studies or enrollment for patients.
- Implementing equip immunotherapy in their current treatment plans.
- Identifying new treatments for historically challenging tumor categories.

#### 1. Please respond regarding how much you agree or disagree that the gaps listed above were addressed.

	Disagree		Agree	
Participating in this educational activity changed your COMPETENCE in the professional practice gaps listed above. [25-3.84]	(0)	(0)	(4) 16.00%	(21) 84.00%

#### 2. Please elaborate on your previous answer. (10)

increased awareness of import of referring patients to tertiary care centers with these various advanced therapeutic modalities discussed this in this webinar.

Learning about Zika was very interesting.

Gained new information in treatment therapy in neuro-oncology

They gave a very good overview of new research, Questioned the use of Dexametasone and use or viral therapy

Introduced new treatment regimens that I was aware of prior to the symposium

This symposium provided important information regarding new treatment regimens that I was not previously aware of.

Na

Identifying new treatments for historically challenging tumor categories.

learned about the upcoming trials using immunotherapy

immunotherapy and innovative trial presentation

#### 3. Please evaluate the effectiveness of the following speakers in improving your competence. (Poor = 1, Excellent = 4)

	Poor	Fair	Good	Excellent
Megan Nelson, MD [24-4.00]	(0)	(0)	(0)	(24)100%
Akshatkumar Mistry, MD [24-4.00]	(0)	(0)	(0)	(24)100%
Brian Williams, MD [24-4.00]	(0)	(0)	(0)	(24)100%

Michael Egger, MD, MPH [24-3.96]	(0)	(0)	(1) 4.17%	(23) 95.83%
Sharmila Nair, PhD [24-3.96]	(0)	(0)	(1) 4.17%	(23) 95.83%

#### 4. Please elaborate on your previous answers. (12)

all gave great reviews, with thought provoking talks.

n/a

Easy to follow, good visual aids

...

All the presenters were outstanding both in their presentation skills as well as the organization of the materials.

All the presenters were very qualified. Their presentation skills were excellent as well as the organization of their materials.

Na

All of them have had an excellent participation

Difficult to understand the last speaker at times.

engaging presenters

dynamic, engaging presenters

#### 5. Please identify a change that you will implement into practice as a result of attending this educational activity (new protocols, different medications, etc.) (16)

Increased importance of referrals to tertiary care centers.

Looking for Zikv for future treatments and urolithon (encourage berries and pomegranates in diet)

n/a

Follow up with more up to date research

Role of dexamethasone may be less important in newly diagnosed glioma.

With this expanded knowledge of newer treatment regimens and a better understanding of the reasoning behind some of the treatment protocols, I will be better equipped to provide and educate my patients as to why particular treatments are prescribed.

I will be able to able to impart this new information to my patients as part of my treatment education when they begin treatment.

Applying new medications.

New Protocols

New protocol

discuss the use of dexamethasone with providers

discussion of use of dexamethasone with providers

Encourage patients to participate and provide information to increase comprehension

Increase patient education to help more enroll and understand

#### 6. How certain are you that you will implement this change? (22)

Very Certain (10-45.45%)

Maybe (3-13.64%)

N/A (2-9.09%)

Certain (7-31.82%)

**7. What topics do you want to hear more about, and what issues(s) in your practice will they address? (14)**

Review of current modalities for spinal surgery, fusion, etc.

BMT

any topics related to neuro field and neurosurgery

Electrophysiology in spine and brain surgeries

Future drug development in CNS tumor

New brain and spine techniques

More applications for immunotherapy treatment regimens for the treatment of solid tumors

Possible new immunotherapy treatment breakthroughs for solid tumor cancers.

I want to hear more about new treatments for patient with cerebrovascular diseases.

Surgical protocols

Na

Neuro-Oncology Immunotherapy Clinical Trials

innovations in immunotherapy

immunotherapy across tumor types

**8. Were the patient recommendations based on acceptable practices in medicine? (22)**

Yes (22-100.00%)

**10. Do you think the presentation was without commercial bias? (23)**

Yes (23-100.00%)

**12. Please indicate any barriers you might encounter in implementing these changes in your practice (select all that apply).**

☐ Lack of support from management [25] (2- 8.00%)

☐ Reimbursement issues [25] (4- 16.00%)

☐ Lack of authority to facilitate such change(s) [25] (1- 4.00%)

☐ Not enough time [25] (4- 16.00%)

☐ I do not anticipate any barriers to implementing these strategies [25] (16- 64.00%)

**13. The format and functionality of this educational activity was effective.**

**(23)**

Yes (22-  
95.65%)

No (1-  
4.35%)

**If no, please explain. (1)**

I participated online and at times the presenters were muffled in their presentations. Even increasing the volume level on my laptop wasn't enough to overcome this issue.

**14. Please provide any additional comments you may have about this educational activity. (8)**

I have enjoyed the various webinars you have offered. As a U. of L. School of Medicine grad who is nearing retirement, these webinars have allowed me to "keep up" without the need to do as much travel. Thank you!

Thank you for this lecture

Thank you for allowing us to participate in these presentations! Thanks for Zoom option (for those who might be on call).

Webinars are very convenient and I can benefit from them

Thank you!

No more comments.

Na

I hope that these new treatment options will soon be available in my country.

As one of the participants of this educational activity, we want to encourage you to implement those ideas that were appropriate to your healthcare environment.

This evaluation is confidential and no individual will be identified by this office (Continuing Medical Education and Professional Development). It will only be used for quality improvement.

Names or contact information of learners will not be shared with any ineligible company or its agents without the explicit consent of the individual learner.

We look forward to seeing you at future University of Louisville events. Thank you very much.